Brain Circuits Determine Destiny in Depression: A Novel Approach to the Psychopharmacology of Wakefulness, Fatigue, and Executive Dysfunction in Major Depressive Disorder

Journal of Clinical Psychiatry

Volumn 64, Issue SUPPL. 14, 2003, Pages 6-17

  Stahl, Stephen M ^a,b   Zhang, Lishu ^a   Damatarca, Cristina ^a   Grady, Meghan ^a  

^a NEUROSCIENCE EDUCATION INSTITUTE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; AMFEBUTAMONE; AMPHETAMINE; ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; ATOMOXETINE; ATYPICAL ANTIPSYCHOTIC AGENT; BUSPIRONE; CENTRAL STIMULANT AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; DOPAMINE; FLUOXETINE; HISTAMINE; LITHIUM; METHYLPHENIDATE; MODAFINIL; MONOAMINE; MONOAMINE OXIDASE INHIBITOR; NEUROLEPTIC AGENT; NEUROTRANSMITTER; NORADRENALIN; NORADRENALIN UPTAKE INHIBITOR; OLANZAPINE; QUETIAPINE; RISPERIDONE; SEROTONIN; SEROTONIN UPTAKE INHIBITOR; THYROID HORMONE; UNCLASSIFIED DRUG; ZIPRASIDONE;

ANHEDONIA; ANOREXIA; ANXIETY DISORDER; APATHY; APPETITE DISORDER; ATTENTION DEFICIT DISORDER; ATTITUDE; BODY WEIGHT DISORDER; BRAIN FUNCTION; BRAIN REGION; CLINICAL TRIAL; COGNITIVE DEFECT; DECISION MAKING; DEMENTIA; DEPRESSION; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; DYSTHYMIA; ENERGY; EXECUTIVE DYSFUNCTION; FATIGUE; GUILT; HUMAN; HYPERSOMNIA; IMAGING; INSOMNIA; MAJOR DEPRESSION; MENTAL CONCENTRATION; MOOD DISORDER; MOTIVATION; NERVE CELL NETWORK; NEUROBIOLOGY; NEUROLOGIC DISEASE; NEUROTRANSMISSION; NEUROTRANSMITTER RELEASE; NONHUMAN; NORADRENERGIC SYSTEM; PAIN; PRIORITY JOURNAL; PSYCHOMOTOR RETARDATION; PSYCHOPHARMACOLOGY; RATING SCALE; REGULATORY MECHANISM; REMISSION; RESTLESSNESS; REVIEW; SCHIZOPHRENIA; SEROTONINERGIC SYSTEM; SEXUAL DYSFUNCTION; SEXUAL FUNCTION; SLEEP DEPRIVATION; SLEEP DISORDER; SOMNOLENCE; SUICIDAL BEHAVIOR; SYMPTOM; WAKEFULNESS; WEIGHT REDUCTION;

ANTIDEPRESSIVE AGENTS; BRAIN; COGNITION DISORDERS; DEPRESSIVE DISORDER, MAJOR; FATIGUE; HUMANS; MENTAL PROCESSES; NEUROTRANSMITTER AGENTS; SLEEP DISORDERS;

EID: 0344033598     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (194)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC: American Psychiatric Association; 1994:321-327
2. Stahl SM. Essential Psychopharmacology: Neuroscientific Basis and Practical Applications. 2nd ed. Cambridge, UK: University of Cambridge; 2000
3. Stahl SM. Deconstructing psychiatric disorders, pt 2: an emerging, neurobiologically based therapeutic strategy for the modern psychopharmacologist [BRAINSTORMS]. J Clin Psychiatry 2003;64:1145-1146
4. Paykel ES, Ramana R, Cooper Z, et al. Residual symptoms after partial remission: an important outcome in depression. Psychol Med 1995;25: 1171-1180
5. Nierenberg AA, Keefe BR, Leslie VC, et al. Residual symptoms in depressed patients who respond acutely to fluoxetine. J Clin Psychiatry 1999;60:221-225
6. Nierenberg AA, DeCecco LM. Definitions of antidepressant treatment response, remission, non-response, partial response, and other relevant outcomes: a focus on treatment-resistant depression. J Clin Psychiatry 2001;62[suppl 16):5-9
7. Fava GA, Fabbri S, Sonino N. Residual symptoms in depression: an emerging therapeutic target. Prog Neuropsychopharmacol Biol Psychiatry 2002;26:1019-1027
8. Paykel ES, Scott J, Teasdale JD, et al. Prevention of relapse in residual depression by cognitive therapy: a controlled trial. Arch Gen Psychiatry 1999;56:829-835
9. Menza M, Marin H, Opper RS. Residual symptoms in depression: can treatment be symptom-specific? J Clin Psychiatry 2003;64:516-523
10. Greden JF. Physical symptoms of depression: unmet needs. J Clin Psychiatry 2003;64(suppl 7):5-11
11. Fava M. Weight gain and antidepressants. J Clin Psychiatry 2000;61 (suppl 11):37-41
12. Zajecka J. Strategies for the treatment of antidepressant-related sexual dysfunction. J Clin Psychiatry 2001;62(suppl 3):35-43
13. Oslin DW, Ten Have TR, Streim JE. Probing the safety of medications in the frail elderly: evidence from a randomized clinical trial of sertraline and venlafaxine in depressed nursing home residents. J Clin Psychiatry 2003;64:875-882
14. Egan MF, Goldberg TE, Kolachana BS, et al. Effect of COMT Val 108/158 met genotype of frontal lobe function and risk for schizophrenia. Proc Natl Acad Sci USA 2001;98:6917-6922
15. Hariri AR, Mattay VS, Tessitore A, et al. Serotonin transporter genetic variation and the response of the human amygdala. Science 2002;297: 400-403
16. Stahl SM. Deconstructing psychiatric disorders, pt 1: genotypes, symptom phenotypes and endophenotypes [BRAINSTORMS]. J Clin Psychiatry 2003; 64:982-983
17. Schidkraut JJ. The catecholamine hypothesis of affective disorders: a review of supporting evidence. Am J Psychiatry 1965;122:509-522
18. Moreno FA, Gelenberg AH, Heninger GR, et al. Tryptophan depletion and depressive vulnerability. Biol Psychiatry 1999;46:498-505
19. Moreno FA, Heninger GR, McGahuey CA, et al. Tryptophan depletion and risk of depression relapse: a prospective study of tryptophan depletion as a potential predictor of depressive episodes. Biol Psychiatry 2000;48: 327-329
20. Moreno FA, McGavin C, Malan TP, et al. Tryptophan depletion selectively reduces CSF 5-HT metabolites in healthy young men: results from single lumbar puncture sampling technique. Int J Neuropsychopharmacol 2000;3:277-283
21. Delgado PL, Miller HL, Salomon RM, et al. Tryptophan-depletion challenge in depressed patients treated with desipramine or fluoxetine: implications for the role of serotonin in the mechanism of antidepressant action. Biol Psychiatry 1999;46:212-220
22. Delgado PL. Depression: the case for a monoamine deficiency. J Clin Psychiatry 2000;61:7-11
23. Delgado PL, Moreno FA, Onate L, et al. Sequential catecholamine and serotonin depletion in mirtazapine-treated depressed patients. Int J Neuropsychopharmacol 2002;5:63-66
24. Miller HL, Delgado PL, Salomon RM, et al. Clinical and biochemical effects of catecholamine depletion on antidepressant-induced remission of depression. Arch Gen Psychiatry 1996;53:117-128
25. Oades RD, Halliday GM. Ventral tegmental (A10) system: neurobiology, 1: anatomy and connectivity. Brain Res 1987;434:117-165
26. Williams SM, Goldman-Rakic PS. Widespread origin of the primate mesofrontal dopamine system. Cereb Cortex 1998;8:321-345
27. Molliver ME. Serotonergic neuronal systems: what their anatomic organization tells us about function. J Clin Psychopharmacol 1987;7(suppl 6):3S-23S
28. Sastry BS, Phillis JW. Inhibition of cerebral cortical neurones by a 5-hydroxytryptaminergic pathway from median raphe nucleus. Can J Neurol Sci 1977;4:151-195
29. Dillier N, Laszlo J, Muller B, et al. Activation of an inhibitory noradrenergic pathway projecting from the locus coeruleus to the cingulate cortex of the rat. Brain Res 1978;154:61-68
30. Berridge CW, Waterhouse BD. The locus coeruleus-noradrenergic system: modulation of behavioral state and state-dependent cognitive processes. Brain Res Brain Res Rev 2003;42:33-84
31. Thase ME, Entsuab AR, Rudolph RL. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiatry 2001;178:234-241
32. Stahl SM, Entsuah R, Rudolph RL. Comparative efficacy between venlafaxine and SSRIs: a pooled analysis of patients with depression. Biol Psychiatry 2002;52:1166-1174
33. Mayberg HS, Liotti M, Brannan SK, et al. Reciprocal limbic-cortical function and negative mood: converging PET findings in depression and normal sadness. Am J Psychiatry 1999;156:675-682
34. Drevets WC. Neuroimaging and neuropathological studies of depression: implications for the cognitive-emotional features of mood disorders. Curr Opin Neurobiol 2001;11:240-249
35. Drevets WC, Bogers W, Raichle ME. Functional anatomical correlates of antidepressant drug treatment assessed using PET measures of regional glucose metabolism. Eur Neuropsychopharmacol 2002;12:527-544
36. Davidson RJ, Lewis DA, Alloy LB, et al. Neural and behavioral substrates of mood and mood regulation. Biol Psychiatry 2002; 52:478-502
37. Liotfi M, Mayberg HS, McGinnis S, et al. Unmasking disease-specific cerebral blood flow abnormalities: mood challenge in patients with remitted unipolar depression. Am J Psychiatry 2002;159:1830-1840
38. Levesque J, Eugene F, Joanette Y, et al. Neural circuitry underlying voluntary suppression of sadness. Biol Psychiatry 2003;53:502-510
39. Lindvall O, Bjorklund A. Anatomy of the dopaminergic neuron systems in the rat brain. Adv Biochem Psychopharmacol 1978;19:1-23
40. Lidov HG, Grzanna R, Molliver ME. The serotonin innervation of the cerebral cortex in the rat: an immunohistochemical analysis. Neuroscience 1980;5:207-227
41. Morrison JH, Molliver ME, Grzarma R, et al. The intra-cortical trajectory of the coeruleo-cortical projection in the rat: a tangentially organized cortical afferent. Neuroscience 1981;6:139-158
42. Ordway GA, Klimek V, Mann JJ. Neurocircuitry of mood disorders. In: Davis KL, Charney D, Coyle JT, et al, eds. Neuropharmacology: The Fifth Generation of Progress. Philadelphia, Pa: Lippincott Williams & Wilkins; 2002:1051-1064
43. Steketee JD. Neurotransmitter systems of the medial prefrontal cortex: potential role in sensitization to psychostimulants. Brain Res Brain Res Rev 2003;41:203-228
44. Davidson RJ, Irwin W, Anderle MJ, et al. The neural substrates of affective processing in depressed patients treated with venlafaxine. Am J Psychiatry 2003;160:64-75
45. Davies J, Lloyd KR, Jones IK, et al. Changes in regional cerebral blood flow with venlafaxine in the treatment of major depression. Am J Psychiatry 2003;160:374-376
46. Saper CB, Chou TC, Scammell TE. The sleep switch: hypothalamic control of sleep and wakefulness. Trends Neurosci 2001;24:726-731
47. Wisor JP, Nishino S, Sora I, et al. Dopaminergic role in stimulant-induced wakefulness. J Neurosci 2001;21:1787-1794
48. Mignot E. A commentary on the neurobiology of the hypocretin/orexin system. Neuropsychopharmacology 2001;14:1075-1081
49. Ripley B, Overeem S, Fujiki N, et al. CSF hypocretin/orexin levels in narcolepsy and other neurological conditions. Neurology 2001;57: 2253-2258
50. Brown RE, Stevens DR, Haas HL. The physiology of brain histamine. Prog Neurobiol 2001;63:637-672
51. Tuomisto L, Lozeva V, Valjakka A, et al. Modifying effects of histamine on circadian rhythms and neuronal excitability. Behav Brain Res 2001; 124:129-135
52. Strecker RE, Nalwalk J, Dauphin LJ, et al. Extracellular histamine levels in the feline preoptic/anterior hypothalamic area during natural sleep-wakefulness and prolonged wakefulness: an in vivo microdialysis study. Neuroscience 2002;113:663-670
53. Haas H, Panula P. The role of histamine and the tuberomamillary nucleus in the nervous system. Hippocampus 2003;13:273-280
54. Pace-Schott EF, Hobson JA. The neurobiology of sleep: genetics, cellular physiology and subcortical networks. Nat Rev Neurosci 2002;3:591-605
55. Ota M. An alpha adrenergic mechanism in the ascending reticular activating system. Jpn J Physiol 1975;25:303-316
56. von Cramon D. Consciousness and disturbances of consciousness. J Neurol 1978;219:1-13
57. Berlucchi G. One or many arousal systems? reflections on some of Giuseppe Moruzzi's foresights and insights about the intrinsic regulation of brain activity. Arch Ital Biol 1997;135:5-14
58. Wisor JP. Disorders of the circadian clock: etiology and possible therapeutic targets. Curr Drug Target CNS Neurol Disord 2002;1:555-566
59. Lin JS, Hou Y, Jouvet M. Potential brain neuronal targets for amphetamine-, methylphenidate-, and modafinil-induced wakefulness, evidenced by c-fos immunocytochemistry in the cat. Proc Natl Acad Sci U S A 1996;93:14128-14133
60. Ishizuka T, Sakamoto Y, Sakurai T, et al. Modafinil increases histamine release in the anterior hypothalamus of rats. Neurosci Lett 2003;339: 143-146
61. Rypma B, D'Esposito M. The roles of prefrontal brain regions in components of working memory: effects of memory load and individual differences. Proc Natl Acad Sci USA 1999;96:6558-6563
62. MacDonald AW III, Cohen JD, Stenger VA, et al. Dissociating the role of the dorsolateral prefrontal and anterior cingulate cortex in cognitive control. Science 2000;288:1835-1838
63. D'Esposito M, Ballard D, Zarahn E, et al. The role of prefrontal cortex in sensory memory and motor preparation: an event-related fMRI study. Neuroimage 2000;11:400-408
64. Lockwood KA, Alexopoulos GS, van Gorp WG. Executive dysfunction in geriatric depression. Am J Psychiatry 2002;159:1119-1126
65. Malhotra AK, Kestler LJ, Mazzanti C, et al. A functional polymorphism on the COMT gene and performance on a test of prefrontal cognition. Am J Psychiatry 2002;159:653-654
66. Krawczyk DC. Contributions of the prefrontal cortex to the neural basis of human decision making. Neurosci Biobehav Rev 2002;26:631-664
67. Cools R, Clark L, Owen AM, et al. Defining the neural mechanisms of probabilistic reversal learning using event-related functional magnetic resonance imaging. J Neurosci 2002;22:4563-4567
68. van den Heuvel OA, Groenewegen HJ, Barkhof F, et al. Frontostriatal system in planning complexity: a parametric functional magnetic resonance version of Tower of London task. Neuroimage 2003;18: 367-374
69. Taylor WD, Steffens DC, McQuoid DR, et al. Smaller orbital frontal cortex volumes associated with functional disability in depressed elders. Biol Psychiatry 2003;53:144-149
70. Dunkin JJ, Leuchter AF, Cook IA, et al. Executive dysfunction predicts nonresponse to fluoxetine in major depression. J Affect Disord 2000;60: 13-23
71. Semkovska M, Bedard MA, Stip E. Hypofrontality and negative symptoms in schizophrenia: synthesis of anatomic and neuropsychological knowledge and ecological perspectives. Encephale 2001;27:405-415
72. McPherson S, Fairbanks L, Tiken S, et al. Apathy and executive function in Alzheimer's disease. J Int Neuropsychol Soc 2002;8:373-381
73. Racagini G, Brunello N. Physiology to functionality: the brain and neurotransmitter activity. Int Clin Psychopharmacol 1999;14(suppl 1): S3-S7
74. Tzschentke TM. Pharmacology and behavioral pharmacology of the mesocortical dopamine system. Prog Neurobiol 2001;63:241-320
75. Dringenberg HC, Vanderwolf CH. Involvement of direct and indirect pathways in electrocorticographic activation. Neurosci Biobehav Rev 1998;22:243-257
76. Philippu A, Prast H. Role of histaminergic and cholinergic transmission in cognitive processes. Drug News Perspect 2001;14:523-529
77. Schweitzer JB, Lee DO, Hanford RB, et al. A positron emission tomography study of methylphenidate in adults with ADHD: alterations in resting blood flow and predicting treatment response. Neuropsychopharmacology 2003;28:967-973
78. Callicott JH, Egan MH, Mattay VS, et al. Abnormal fMI response of the dorsolateral prefrontal cortex in cognitively intact siblings of patients with schizophrenia. Am J Psychiatry 2003;160:709-719
79. Drummond SP, Salamat JS, Lopez C, et al. Role of task difficulty in cerebral compensation following sleep deprivation. In: Abstract Supplement of the 17th Annual Meeting of the Associated Professional Sleep Societies; June 3-8, 2003; Chicago, Ill
80. Galynker II, Dutta E, Vilkas N, et al. Hypofrontality and negative symptoms in patients with dementia of Alzheimer type. Neuropsychiatry Neuropsychol Behav Neurol 2000;13:53-59
81. Tylee AT, Freeling P, Kerry S. Why do general practitioners recognize major depression in one woman patient yet miss it in another? Br J Gen Pract 1993;43:327-330
82. Maurice-Tyson S, Verdoux H, Gay B, et al. How to improve recognition and diagnosis of depressive syndromes using international diagnostic criteria. Br J Gen Pract 1998;48:1245-1246
83. Emmons CA, Fetting JH, Zonderman AB. A comparison of the symptoms of medical and psychiatric inpatients matched on the Beck Depression Inventory. Gen Hosp Psychiatry 1987;9:398-404
84. Swindle R, Kroenke K, Braun LA. Energy and improved workplace productivity in depression. In: Farquhar I. Summers K, Sorkin A, eds. Investing in Health: The Social and Economic Benefits of Health Care Innovation. vol 14. New York, NY: Elsevier Science Ltd; 2001:323-341
85. Geyer MA, Puerto A, Menkes DB, et al. Behavioral studies following lesions of the mesolimbic and mesostriatal serotonergic pathways. Brain Res 1976;106:257-269
86. Jones GH, Robbins TW. Differential effects of mesocortical, mesolimbic, and mesostriatal dopamine depletion on spontaneous, conditioned, and drug-induced locomotor activity. Pharmacol Biochem Behav 1992;43:887-895
87. Waterhouse BD, Lin CS, Burne RA, et al. The distribution of neocortical projection neurons in the locus coeruleus. J Comp Neurol 1983;217: 418-431
88. Dray A. Serotonin in the basal ganglia: functions and interactions with other neuronal pathways. J Physiol Paris 1981;77:393-403
89. Wall PD, Melzack R. Textbook of Pain. 4th ed. New York: Churchill Livingston; 1999
90. Millan MJ. Descending control of pain. Prog Neurobiol 2002;66: 355-474
91. Stahl SM. The psychopharmacology of energy and fatigue [BRAINSTORMS]. J Clin Psychiatry 2002;63:7-8
92. MacHale SM, Lawrie SM, Cavanagh JT, et al. Cerebral perfusion in chronic fatigue syndrome and depression. Br J Psychiatry 2000;176: 550-556
93. Adamec RE. Hypothalamic and extrahypothalamic substrates of predatory attack: suppression and the influence of hunger. Brain Res 1976;106:57-69
94. Bagnasco M, Kalra PS. Kalra SP. Ghrelin and leptin pulse discharge in fed and fasted rats. Endocrinology 2002;143:726-729
95. Gold PW, Chrousos GP. Organization of the stress system and its dysregulation in melancholic and atypical depression: high vs low CRH/NE states. Mol Psychiatry 2002;7:254-275
96. Koob GF, Le Moal M. Drug abuse: hedonic homeostatic dysregulation. Science 1997;278:42-58
97. Leshner AI, Koob GF. Drugs of abuse and the brain. Proc Assoc Am Physicians 1999;111:99-108
98. Arango V, Underwood MD, Mann JJ. Serotonin brain circuits involved in major depression and suicide. Prog Brain Res 2002;136:443-453
99. Oquendo MA, Placidi GP, Malone KM, et al. Positron emission tomography of regional brain metabolic responses to a serotonergic challenge and lethality of suicide attempts in major depression. Arch Gen Psychiatry 2003;60:14-22
100. Lytle LD, Messing RB. Appetite in the regulation of food intake for energy (animal and man). Prog Food Nutr Sci 1976;2:49-58
101. Kaye WH, Weltzin TE. Neurochemistry of bulimia nervosa. J Clin Psychiatry 1991;52(suppl 10):21-28
102. Stahl SM. Neuropharmacology of obesity: my receptors made me eat it [BRAINSTORMS]. J Clin Psychiatry 1998;59:447-448
103. Stahl SM. How to appease the appetite of psychotic drugs [BRAINSTORMS]. J Clin Psychiatry 1998;59:500-501
104. Dantchev N, Widlocher DJ. The measurement of retardation in depression. J Clin Psychiatry 1998;59(suppl 14):19-25
105. Sobin C, Sackeim HA. Psychomotor symptoms of depression. Am J Psychiatry 1997;154:4-17
106. Brody AL, Barsom MW, Bota RG, et al. Prefrontal-subcortical and limbic circuit mediation of major depressive disorder. Semin Clin Neuropsychiatry 2001;6:102-112
107. Kendler KS. Major depression and generalised anxiety disorder. Same genes, (partly) different environments: revisited. Br J Psychiatry 1996;(suppl 30):68-75
108. Fava M, Rankin MA, Wright EC, et al. Anxiety disorders in major depression. Compr Psychiatry 2000;41:97-102
109. Bagby RM, Ryder AG, Cristi C. Psychosocial and clinical predictors of response to pharmacotherapy for depression. J Psychiatry Neurosci 2002;27:250-257
110. Fava GA, Grandi S, Canestrari R, et al. Prodromal symptoms in primary major depressive disorders. J Affect Disord 1990;19:149-152
111. Gorman JM, Kent JM, Sullivan GM, et al. Neuroanatomical hypothesis of panic disorder: revised. Am J Psychiatry 2000;157:493-505
112. Stahl SM. Independent actions on fear circuits may lead to therapeutic synergy for anxiety when combining serotonergic and GABAergic agents [BRAINSTORMS]. J Clin Psychiatry 2002;63:854-855
113. Seidenbecher T, Laxmi TR, Stork O, et al. Amygdalar and hippocampal theta rhythm synchronization during fear memory retrieval. Science 2003;301:846-850
114. Charney DS. Neuroanatomical circuits modulating fear and anxiety behaviors. Acta Psychiatr Scand Suppl 2003;417:38-50
115. Graeff FG. Neuroanatomy and neurotransmitter regulation of defensive behaviors and related emotions in mammals. Braz J Med Biol Res 1994;27:811-829
116. Valentino RJ, Chen S, Zhu Y, et al. Evidence for divergent projections to the brain noradrenergic system and the spinal parasympathetic system from Barrington's nucleus. Brain Res 1996;732:1-15
117. Redmond DE Jr, Huang YH. Current concepts, 2: new evidence for a locus coeraleus-norepinephrine connection with anxiety. Life Sci 1979;25:2149-2162
118. Tanaka M, Yoshida M, Emoto H, et al. Noradrenaline systems in the hypothalamus, amygdala and locus coeruleus are involved in the provocation of anxiety: basic studies. Eur J Pharmacol 2000;405:397-406
119. Connor KM, Davidson JR. Generalized anxiety disorder: neurobiological and pharmacotherapeutic perspectives. Biol Psychiatry 1998;44:1286-1294
120. Cameron OG, Smith CB, Lee MA, et al. Adrenergic status in anxiety disorders: platelet alpha 2-adrenergic receptor binding, blood pressure, pulse, and plasma catecholamines in panic and generalized anxiety disorder patients and in normal subjects. Biol Psychiatry 1990;28:3-20
121. Eison MS. Serotonin: a common neurobiologic substrate in anxiety and depression. J Clin Psychopharmacol 1990;10(suppl 3):26S-30S
122. Ohayon MM, Schatzberg AF. Using chronic pain to predict depressive morbidity in the general population. Arch Gen Psychiatry 2003;60: 39-47
123. Juhl JH. Fibromyalgia and the serotonin pathway. Altem Med Rev 1998;3:367-375
124. Bradley LA, McKendree-Smith NL, Alarcon GS, et al. Is fibromyalgia a neurologic disease? Curr Pain Headache Rep 2002;6:106-114
125. Stahl SM. Does depression hurt? [BRAINSTORMS]. J Clin Psychiatry 2002;63:273-274
126. Damatarca C, Stahl SM. Pain and depression: bridging the body and mind. Depress: Mind Body 2003;1:7-13
127. Hirschfeld RM, Dunner DL, Keitner G, et al. Does psychosocial functioning improve independent of depressive symptoms? a comparison of nefazodone, psychotherapy, and their combination. Biol Psychiatry 2002;51:123-133
128. Mintz J, Mintz LI, Arruda MJ, et al. Treatments of depression and the functional capacity to work. Arch Gen Psychiatry 1992;49:761-768
129. Judd LL, Akiskal HS, Maser JD, et al. Major depressive disorder: a prospective study of residual subthreshold depressive symptoms as predictor of rapid relapse. J Affect Disord 1998;50:97-108
130. Lecrubier Y. How do you define remission? Acta Psychiatr Scand 2002:106(suppl 415):7-11
131. Paykel ES. Achieving gains beyond response. Acta Psychiatr Scand 2002;106(suppl 415):12-17
132. Fredman SJ, Fava M, Kienke AS, et al. Partial response, nonresponse, and relapse with selective serotonin reuptake inhibitors in major depression: a survey of current "next-step" practices. J Clin Psychiatry 2000;61:403-408
133. Meyers BS, Mattis S, Gabriele M, et al. Effects of nortriptyline on memory self-assessment and performance in recovered elderly depressives. Psychopharmacol Bull 1991;27:295-299
134. Levkovitz Y, Caftori R, Avital A, et al. The SSRIs drug fluoxetine, but not the noradrenergic tricyclic drug desipramine, improves memory performance during acute major depression. Brain Res Bull 2002;58: 345-350
135. Fava GA. Anxiety sensitivity. Am J Psychiatry 1996;153:1109-1110
136. Cardieux RJ. Practical management of treatment-resistant depression. Am Fam Physician 1998;58:2059-2062
137. Ostroff RB, Nelson JC. Risperidone augmentation of selective serotonin reuptake inhibitors in major depression. J Clin Psychiatry 1999;60: 256-259
138. Nelson JC. Augmentation strategies in depression 2000. J Clin Psychiatry 2000;61(suppl 2):13-19
139. Baker M, Dorzab J, Winokur G, et al. Depressive disease: classification and clinical characteristics. Compr Psychiatry 1971;12:354-365
140. Reynolds CF III, Kupfer DJ. Sleep research in affective illness: state of the art circa 1987. Sleep 1987;10:199-215
141. Horwath E, Johnson J, Weissman MM, et al. The validity of major depression with atypical features based on a community study. J Affect Disord 1992;26:117-125
142. Tylee AT, Gastpar M, Lepine JP, et al, for the DEPRES Steering Committee. DEPRES II (Depression Research in European Society II): a patient survey of the symptoms, disability and current management of depression in the community. Int Clin Psychopharmacol 1999;14: 139-151
143. Monti JM. Effect of a reversible monoamine oxidase-A inhibitor (moclobemide) on sleep of depressed patients. Br J Psychiatry Suppl 1989;6:61-65
144. Sharpley AL, Cowen PJ. Effect of pharmacologic treatments on the sleep of depressed patients. Biol Psychiatry 1995;37:85-98
145. Fava GA, Grandi S, Zielezny M, et al. Cognitive behavioral treatment of residual symptoms in primary major depressive disorder. Am J Psychiatry 1994;151:1295-1299
146. Addington AM, Gallo JJ, Ford DE, et al. Epidemiology of unexplained fatigue and major depression in the community: the Baltimore ECA follow-up, 1981-1994. Psychol Med 2001;31:1037-1044
147. Austin MP, Mitchell P, Goodwin GM. Cognitive deficits in depression: possible implications for functional neuropathology. Br J Psychiatry 2001;178:200-206
148. Porter RJ, Gallagher P, Thompson JM, et al. Neurocognitive impairment in drug-free patients with major depressive disorder. Br J Psychiatry 2003;182:214-220
149. Bornstein RA, Baker GB, Douglass AB. Depression and memory in major depressive disorder. J Neuropsychiatry Clin Neurosci 1991;3: 78-80
150. Basso MR, Bornstein RA. Neuropsychological deficits in psychotic versus nonpsychotic unipolar depression. Neuropsychology 1999;13:69-75
151. Fava M, Davidson KG. Definition and epidemiology of treatment-resistant depression. Psychiatr Clin North Am 1996;19:179-200
152. Li XM, Perry KW, Wong DT, et al. Olanzapine increases in vivo dopamine and norepinephrine release in rat prefrontal cortex, nucleus accumbens and striatum. Psychopharmacology 1998;136:153-161
153. Zhang W, Perry KW, Wong PT, et al. Synergistic effects of olanzapine and other antipsychotic agents in combination with fluoxetine on norepinephrine and dopamine release in rat prefrontal cortex. Neuropsychopharmacology 2000;23:250-262
154. Bymaster FP, Katner JS, Nelson DL, et al. Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology 2002;27:699-711
155. De Saint Hilaire A, Orosco M, Rouch C, et al. Variations in extracellular monoamines in the prefrontal cortex and medial hypothalamus after modafinil administration: a microdialysis study in rats. NeuroReport 2001;12:3533-3537
156. Moron JA, Brockington A, Wise RA, et al. Dopamine uptake through the norepinephrine transporter in brain regions with low levels of the dopamine transporter: evidence from knock-out mouse lines. J Neurosci 2002;22:389-395
157. Stahl SM. Neurotransmission of cognition, pt 1. Dopamine is a hitch-hiker in frontal cortex: norepinephrine transporters regulate dopamine [BRAINSTORMS]. J Clin Psychiatry 2003;64:4-5
158. Stahl SM. Neurotransmission of cognition, pt 2. Selective NRIs are smart drugs: exploiting regionally selective actions on both dopamine and norepinephrine to enhance cognition [BRAINSTORMS]. J Clin Psychiatry 2003;64:110-111
159. Thase ME. Fiber-type-related differences in the enzymes of a proposed substrate cycle. Biochim Biophys Acta 1998;1363:224-230
160. Bodkin JA, Lasser RA, Wines JD Jr, et al. Combining serotonin reuptake inhibitors and bupropion in partial responders to antidepressant monotherapy. J Clin Psychiatry 1997;58:137-145
161. DeBattista C, Solvason HB, Kendrick E, et al. Modafinil as adjunctive in treatment of fatigue and hypersomnia in major depression. In: New Research Program and Abstracts of the 154th Annual Meeting of the American Psychiatric Association; May 9, 2001; New Orleans, La. Abstract NR532:144
162. Ferraro L, Antonelli T, O'Connor WT, et al. Modafinil: an antinarcoleptic drug with a different neurochemical profile to d-amphetamine and dopamine uptake blockers. Biol Psychiatry 1997;42:1181-1183
163. Ferraro L, Fuxe K, Tanganelli S, et al. Amplification of cortical serotonin release: a further neurochemical action of the vigilance-promoting drug modafinil. Neuropharmacology 2000;39:1974-1983
164. Ferraro L, Fuxe K, Tanganelli S, et al. Differential enhancement of dialysate serotonin levels in distinct brain regions of the awake rat by modafinil: possible relevance for wakefulness and depression. J Neurosci Res 2002;68:107-112
165. Engber TM, Dennis SA, Jones BE, et al. Brain regional substrates for the actions of the novel wake-promoting agent modafinil in the rat: comparison with amphetamine. Neuroscience 1998;87:905-911
166. Menza MA, Kaufman KR, Castellanos A. Modafinil augmentation of antidepressant treatment in depression. J Clin Psychiatry 2000;61: 378-381
167. Markovitz PJ, Wagner S. An open-label trial of modafinil augmentation in patients with partial response to antidepressant therapy. J Clin Psychopharmacol 2003;23:207-209
168. Bastuji H, Jouvet M. Successful treatment of idiopathic hypersomnia and narcolepsy with modafinil. Prog Neuropsychopharmacol Biol Psychiatry 1988;12:695-700
169. Broughton RJ, Fleming JA, George CF, et al. Randomized, double blind, placebo-controlled crossover trial of modafinil in the treatment of excessive daytime sleepiness in narcolepsy. Neurology 1997;49: 444-451
170. Pack AI, Black JE, Schwartz JR, et al. Modafinil as adjunct therapy for daytime sleepiness in obstructive sleep apnea. Am J Respir Crit Care Med 2001;164:1675-1681
171. Roth T, Roehrs TA. Etiologies and sequelae of excessive daytime sleepiness. Clin Ther 1996;18:562-576
172. Bardwell WA, Moore P, Ancoli-Israel S, et al. Fatigue in obstructive sleep apnea: driven by depressive symptoms instead of apnea severity? Am J Psychiatry 2003;160:350-355
173. Damian MS, Ferlach A, Schmidt F, et al. Modafinil for excessive daytime sleepiness in myotonic dystrophy. Neurology 2001;56:794-796
174. MacDonald JR, Hill JD, Tamopolsky MA. Modafinil reduces excessive somnolence and enhances mood in patients with myotonic dystrophy. Neurology 2002;59:1876-1880
175. Krupp L, LaRocca NG, Muir-Nash J, et al. The fatigue severity scale: application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol 1989;36:1121-1123
176. Miller MS, Contreras PC, Roux S, et al. Modafinil improves cognitive function in rats measured by a delayed alternation task. In: Abstract Supplement of the 14th Annual Meeting of the Associated Professional Sleep Societies; June 17-22, 2000; Las Vegas, Nev. Abstract A209
177. Turner DC, Robbins TW, Clark L, et al. Cognitive enhancing effects of modafinil in healthy volunteers. Psychopharmacology (Berl) 2003;165:260-269
178. Thomas RJ, Kwong K. Effects of modafinil on working memory after sleep deprivation: a functional magnetic resonance imaging study. Presented at the 16th annual meeting of the Associated Professional Sleep Societies; June 2002; Seattle, Wash
179. Thomas RJ, Kwong KK. Effects of modafinil on working memory load responses after overnight sleep deprivation: a functional magnetic resonance imaging study. In: Abstract Supplement of the 17th Annual Meeting of the Associated Professional Sleep Societies; June 3-8, 2003; Chicago, Ill. Abstract 0465.I
180. Taylor FB, Russo J. Efficacy of modafinil compared to dextroamphetamine for the treatment of attention deficit hyperactivity disorder in adults. J Child Adolesc Psychopharmacol 2000;10:311-320
181. Rugino TA, Copley TC. Effects of modafinil in children with attention-deficit/hyperactivity disorder: an open-label study. J Am Acad Child Adolesc Psychiatry 2001;40:230-235
182. Makela EH, Miller K, Cutlip WD II. Three case reports of modafinil use in treating sedation induced by antipsychotic medications [letter]. J Clin Psychiatry 2003;64:485-486
183. Webster L, Andrew M, Stoddard G. Modafinil treatment of opioid-induced sedation. Pain Med 2003;4:135-140
184. Shelton RC, Tollefson GD, Tohen M, et al. A novel augmentation strategy for treatment-resistant major depression. Am J Psychiatry 2001;158:131-134
185. Ichikawa J, Li Z, Dai J, et al. Atypical antipsychotic drugs, quetiapine, iloperidone, and melperone, preferentially increase dopamine and acetylcholine release in rat medial prefrontal cortex: role of 5-HT1A receptor agonism. Brain Res 2002;956:349-357
186. Harvey PD, Green MF, McGurk SR, et al. Changes in cognitive functioning with risperidone and olanzapine treatment: a large-scale, double-blind, randomized study. Psychopharmacology (Berl) 2003;167: 519-526
187. Xu F, Gainetdinov RR, Wetsel WC, et al. Mice lacking the norepinephrine transporter are supersensitive to psychostimulants. Nat Neurosci 2000;3:465-471
188. Tanda G, Pontieri FE, Frau R, et al. Contribution of blockade of the noradrenaline carrier to the increase of extracellular dopamine in the rat prefrontal cortex by amphetamine and cocaine. Eur J Neurosci 1997;9:2077-2085
189. Worsley JN, Moszczynska A, Falardeau P, et al. Dopamine D1 receptor protein is elevated in nucleus accumbens of human, chronic methamphetamine users. Mol Psychiatry 2000;5:664-672
190. Everitt BJ, Wolf ME. Psychomotor stimulant addiction: a neural systems perspective. J Neurosci 2002;22:3312-3320
191. Murphy CA, Russig H, Pezze MA, et al. Amphetamine withdrawal modulates FosB expression in mesolimbic dopaminergic target nuclei: effects of different schedules of administration. Neuropharmacology 2003;44:926-939
192. Wagner GJ, Rabkin JG, Rabkin R. Dextroamphetamine as a treatment for depression and low energy in AIDS patients: a pilot study. J Psychosom Res 1997;42:407-411
193. Wagner GJ, Rabkin R. Effects of dextroamphetamine on depression and fatigue in men with HIV: a double-blind, placebo-controlled trial. J Clin Psychiatry 2000;61:436-440
194. Breitbart W, Rosenfeld B, Kaim M, et al. A randomized, double-blind, placebo-controlled trial of psychostimulants for the treatment of fatigue in ambulatory patients with human immunodeficiency virus disease. Arch Intern Med 2001;161:411-420